Megan Hollasch

Luciano J. Costa, MD, PhD, discussed extended follow-up data from the trial and explained how the results may affect frontline treatment decisions in multiple myeloma.

HER2 amplification appears to be prognostic in patients with RAS wild-type metastatic colorectal cancer but may not be predictive of survival benefit as a first-line treatment option in combination with panitumumab vs standard-of-care bevacizumab.

The novel HER2-targeted bispecific antibody zanidatamab in combination with docetaxel demonstrated efficacy with a manageable safety profile as first-line treatment in patients with advanced HER2-positive breast cancer.

Zanubrutinib demonstrated long-term efficacy with superior tolerability compared with ibrutinib for the treatment of patients with symptomatic Waldenström macroglobulinemia regardless of CXCR4 or MYD88 mutational status.

Pembrolizumab demonstrated long-term survival benefit compared with ipilimumab in patients with unresectable stage III/IV melanoma who received up to 1 prior systemic therapy.

Treatment with the all-oral triplet of tucatinib, letrozole, and palbociclib yielded clinically meaningful efficacy results and had an acceptable safety profile in patients with hormone receptor–positive, HER2-positive metastatic breast cancer.

Yasser Mohamed Ali Ged, MBBS, highlights the early efficacy seen in patients with renal cell carcinoma with BAP1 mutations and next steps for the ORCHID trial.

Finding effective treatments beyond the first line for patients with locally advanced or metastatic estrogen receptor-positive, HER2-negative breast cancer and an ESR1 mutation remains a challenge following development of resistance to agents.

David F. McDermott, MD, discusses how combining HIF-2α inhibition with CDK4/6 inhibition could be an effective treatment regimen in patients with renal cell carcinoma and shared details from the LITESPARK-024 trial.

Trastuzumab plus ramucirumab and paclitaxel yielded promising efficacy and a manageable safety profile among patients with previously treated HER2-positive advanced gastric/gastroesophageal junction cancer.

Zipalertinib demonstrated promising efficacy as well as an acceptable safety profile in heavily pretreated patients with recurrent or metastatic non–small cell lung cancer with EGFR exon 20 insertions.

Amira Marouf, MD, PhD student, describes the nature of a comparative analysis conducted based on propensity score matching, and discussed the main takeaways regarding the efficacy of PD-1 inhibitors for patients with relapsed/refractory ENKTCL.

Neoadjuvant treatment with nivolumab plus platinum-based chemotherapy followed by adjuvant nivolumab increased pathological complete response rates and prolonged survival compared with neoadjuvant chemotherapy alone in patients with resectable stage IIIA/B non–small cell lung cancer.

Sugemalimab plus chemotherapy demonstrated statistically significant and clinically meaningful improvements in progression-free survival and overall survival vs placebo plus chemotherapy for the first-line treatment of patients with stage IV non–small cell lung cancer irrespective of PD-L1 expression level and tumor pathological type.

Omid Hamid, MD, discusses the key efficacy and safety findings for the combination of fianlimab plus cemiplimab in patients with advanced melanoma.

Marwan G. Fakih, MD, discusses how the BASECAMP-1 and EVEREST-1 trials will work in concert and dives into the unique mechanism of action of A2B530.

Lakshmi Nayak, MD, discusses the treatment landscape for patients with primary central nervous system lymphoma and how tirabrutinib may serve as an option for those with relapsed/refractory disease.

Two-year follow-up data from the RELATIVITY-047 trial showed a continued benefit for patients with previously untreated, unresectable, or metastatic melanoma receiving nivolumab plus relatlimab vs nivolumab monotherapy supporting the use of the combination.

Treatment with avutometinib plus defactinib elicited high responses among patients with recurrent low grade serous ovarian cancer compared with avutometinib monotherapy, supporting the use of the combination in this patient population regardless of KRAS status, according to data from the RAMP 201 trial.

Longer follow-up data from the phase 2 ELAINE-2 study demonstrated that treatment with lasofoxifene and abemaciclib resulted in clinically meaningful antitumor activity as well as continued tolerability with no new safety signals for patients with estrogen receptor-positive HER2-negative ESR1-mutated breast cancer who previously received CDK4/6 inhibitors.

Findings from a subgroup analysis of the phase 3 EMERALD trial presented during the 2023 ASCO Annual Meeting demonstrated elacestrant elicited prolonged progression-free survival compared with standard-of-care therapy for patients with estrogen receptor-positive, HER2-negative non-detected ESR1 mutated breast cancer who experienced disease progression within 6 months of CDK4/6 inhibitor treatment plus endocrine therapy.

Triplet therapy with cabozantinib, nivolumab, and ipilimumab demonstrated clinical meaningful activity in patients with renal cell carcinoma with variant histologies.

Ilyas Sahin, MD, details the preclinical findings from the study and highlighted how these data could help inform future studies for the treatment of patients with MDM2-overexpressing solid tumors.

Amanda Bloomer, PhD, highlights the growing need for more research for this growing patient population and the age-specific findings that were seen in the ColoCare trial.

Nusayba Bagegni, MD, details ongoing research and possibilities for the treatment landscape in the future, which includes investigating escalating approaches through more research in clinical trials.

Sacituzumab govitecan-hziy produced comparable efficacy outcomes for patients with metastatic triple-negative breast cancer who had a higher incidence of grade 2 or 3 diarrhea and neutropenia vs patients in the overall population, according to a post hoc analysis of the phase 3 ASCENT trial presented at the 2023 ESMO Breast Cancer Annual Congress.

Adjuvant abemaciclib with endocrine therapy led to a tolerable safety profile in patients with hormone receptor-positive, HER2-negative, node-positive, high-risk, early breast cancer,

Treatment with adjuvant anastrozole over a 10-year period remained tolerable and increased disease-free survival rates in postmenopausal women with hormone receptor–positive breast cancer, according to data from the phase 3 AERAS trial.

Abhinav Deol, MD, gives insight on CAR T-cell therapy’s future role in the treatment landscape for multiple myeloma and what needs to be done to push the needle forward.

Bently Doonan, MD, discusses how CA-4948 can penetrate the blood-brain barrier and interact with the tumor microenvironment, and how this approach may open doors for patients with melanoma who have brain metastases.